U.S. Markets close in 1 hr 37 mins

Before You Buy TherapeuticsMD, Inc. (NASDAQ:TXMD), Consider Its Volatility

Simply Wall St

Want to participate in a short research study ? Help shape the future of investing tools and you could win a $250 gift card!

If you own shares in TherapeuticsMD, Inc. ( NASDAQ:TXMD ) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first type is company specific volatility. Investors use diversification across uncorrelated stocks to reduce this kind of price volatility across the portfolio. The second sort is caused by the natural volatility of markets, overall. For example, certain macroeconomic events will impact (virtually) all stocks on the market.

Some stocks see their prices move in concert with the market. Others tend towards stronger, gentler or unrelated price movements. Beta is a widely used metric to measure a stock's exposure to market risk (volatility). Before we go on, it's worth noting that Warren Buffett pointed out in his 2014 letter to shareholders that 'volatility is far from synonymous with risk.' Having said that, beta can still be rather useful. The first thing to understand about beta is that the beta of the overall market is one. A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

See our latest analysis for TherapeuticsMD

What does TXMD's beta value mean to investors?

Zooming in on TherapeuticsMD, we see it has a five year beta of 1.87. This is above 1, so historically its share price has been influenced by the broader volatility of the stock market. Based on this history, investors should be aware that TherapeuticsMD are likely to rise strongly in times of greed, but sell off in times of fear. Share price volatility is well worth considering, but most long term investors consider the history of revenue and earnings growth to be more important. Take a look at how TherapeuticsMD fares in that regard, below.

NasdaqGS:TXMD Income Statement, July 16th 2019

Could TXMD's size cause it to be more volatile?

TherapeuticsMD is a small cap stock with a market capitalisation of US$598m. Most companies this size are actively traded. It is quite common to see a small-cap stock with a beta greater than one. In part, that's because relatively few investors can influence the price of a smaller company, compared to a large company.

What this means for you:

Since TherapeuticsMD tends to moves up when the market is going up, and down when it's going down, potential investors may wish to reflect on the overall market, when considering the stock. In order to fully understand whether TXMD is a good investment for you, we also need to consider important company-specific fundamentals such as TherapeuticsMD’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook : What are well-informed industry analysts predicting for TXMD’s future growth? Take a look at our free research report of analyst consensus for TXMD’s outlook.
  2. Past Track Record : Has TXMD been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of TXMD's historicals for more clarity.
  3. Other Interesting Stocks : It's worth checking to see how TXMD measures up against other companies on valuation. You could start with this free list of prospective options .

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com . This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.